Extrachromosomal DNA drives molecular and clinical heterogeneity in hepatocellular carcinoma: a multi-omics analysis and prognostic model development - PubMed
3 months ago
- #Extrachromosomal DNA
- #Prognostic model
- #Hepatocellular carcinoma
- Extrachromosomal DNA (ecDNA) is a key factor in cancer evolution and heterogeneity, particularly in hepatocellular carcinoma (HCC).
- EcDNA-positive HCC tumors exhibit increased vascular invasion, higher AFP levels, and more TP53 mutations.
- These tumors show unique activation of proliferation pathways, decreased stromal infiltration, and heightened immune activation.
- A six-gene signature (RNF186, BMP6, AOC1, FBLL1, MYBL2, DNASE1L3) was developed for prognostic purposes.
- DNASE1L3 was found to be downregulated in HCC and suppresses proliferation and migration of Hep3B2.1-7 cells.
- The study provides insights into ecDNA-driven tumor heterogeneity and offers a prognostic model for personalized HCC management.